Publications
T-Cells, VST Cells
G-Rex®10
Publication Date: January 16, 2015
A xeno-free, chemically defined serum replacement, CTS Immune Cell SR, can stand in for human or fetal bovine serum when expanding T cells for adoptive therapy. Combined with OpTmizer medium, it supported expansion of CD3/CD28 bead-activated and rapid-protocol polyclonal T cells, and the cells were readily transduced with a lentiviral vector. In seven EBV-seropositive donors it raised cell yield and the frequency of CD8 T cells specific for the subdominant LMP1&2 and EBNA1 antigens compared with RPMI with FBS, and favoured a central memory phenotype. CMV-specific T cells showed similar yield, frequency and polyfunctionality. In G-Rex®10 flasks, EBV-specific cultures expanded 9- to 13-…
Publications
TIL Cells
G-Rex®100M
Publication Date: November 1, 2014
Melanoma tumor-infiltrating lymphocytes can be expanded with K562-derived artificial antigen-presenting cells instead of pooled irradiated donor PBMC feeders, with similar expansion and function. Cells engineered to express CD86, CD137-ligand, CD64 and membrane-bound IL-15 were loaded with anti-CD3 and used at a 1:50 TIL-to-aAPC ratio for a 14-day rapid expansion. Across 16 patient samples, fold expansion did not differ statistically from the 1:200 PBMC-feeder protocol, while the CD8+ fraction rose. T-cell receptor V-chain diversity, granzyme B and perforin content, tumor killing and IFN-γ release were comparable. Expansion in G-Rex® 100M flasks (12 TIL lines) also matched feeders, with a…
Publications
CAR T Cells
Publication Date: October 1, 2014
Canine T cells can be activated, expanded and engineered with a HER2-specific chimeric antigen receptor ex vivo, and the resulting cells kill HER2-positive canine osteosarcoma cells. Peripheral blood mononuclear cells were stimulated with PHA, IL-21 and irradiated K562 artificial antigen-presenting cells; seven days later cultures were 83% CD3-positive. Restimulation in G-Rex® devices produced an average 103-fold expansion in 8 days (n=8), giving 2.4 × 10^8 to 1.6 × 10^9 cells from about 1.4 × 10^7 PBMCs. Retroviral transduction on day 3 gave 26.5% average CAR expression (n=6). HER2-CAR T cells secreted more IFNγ and lysed all tested HER2-positive canine osteosarcoma lines, and a CAR with…
Publications
CAR T Cells
G-Rex®10
Publication Date: September 1, 2014
Non-virally engineered CD19-specific CAR T cells generated with piggyBac transposons can kill Philadelphia chromosome–positive acute lymphoblastic leukemia cells, including tyrosine kinase inhibitor-resistant T315I-mutated lines. Mononuclear cells from 10 mL of healthy donor blood were nucleofected, CAR-selected and expanded for 21 days in serum-free medium with IL-15 and autologous feeder cells, yielding 1.28 × 10^8 cells, 71.3% CD8-positive. In seven-day co-cultures with seven leukemia lines at a 1:5 effector-to-target ratio, CAR T cells almost completely eliminated tumor cells, with fewer than 0.1% CD19-positive cells remaining. They also expanded about 16-fold after ten days without a…
Publications
CD34 Cells
G-Rex®10
Publication Date: August 29, 2014
Cell-permeable Tat-MYC and Tat-Bcl-2 fusion proteins expanded mouse and human hematopoietic stem and progenitor cells ex vivo without genetic modification. In cultures of bone marrow from 5-fluorouracil-treated mice, c-Kit+/Sca-1+ lineage-negative cells expanded on average 87-fold over 21 days. Human CD34+ cells expanded 16.6-fold from cord blood, 13.6-fold from G-CSF mobilized blood and about 10-fold from adult bone marrow after 12 days, versus 8.1-fold and 7.3-fold with a control protein for cord blood and mobilized blood. Expanded cells engrafted irradiated immunodeficient mice, produced lymphoid and myeloid cells and could be serially transplanted, and no leukemias were observed in mi…
Publications
Other
Publication Date: July 1, 2014
Human islets shipped at twenty-fold higher density in gas-permeable silicone rubber membrane vessels kept their viability after overnight transport. Islets from two manufacturing centers were sent to a distant laboratory in 10 cm² vessels at a low density of 200 IE/cm² or a high density of 4000 IE/cm², with a microcentrifuge tube as negative control. Six shipments were assessed. High density gave a 20-fold higher islet count and a 13-fold higher DNA content than low density, yet oxygen consumption rate per DNA did not fall, whereas the tube control was significantly lower (P = .03). In one shipment returned after 4 days in transit, high-density islets showed normal glucose-stimulated insu…
Publications
CAR T Cells
G-Rex®10, G-Rex®100M, G-Rex®500M, G-Rex®5M
Publication Date: May 14, 2014
Culturing K562 suspension cells in G-Rex® devices under optimized conditions gave about 100-fold expansion in 10 days from one up-front addition of 10 mL medium per cm², with no feeding. Cell density plateaued near 1.4 × 10^7 cells/cm² regardless of seeding density, and the lowest workable seeding density, 1.25 × 10^5 cells/cm², gave the greatest fold expansion (109.76 ± 3.9). Glucose depletion in the medium allowed cell numbers to be estimated without resuspending the culture. Cultures in G-Rex® 5, 100M and 500M devices reached similar densities of 12.1 to 12.9 × 10^6 cells/cm², and a multicenter study in G-Rex® 100M reproduced the output. The GatheRex recovered 1269.3 ± 91.4 × 10^6 cell…
Publications
TIL Cells
Publication Date: May 9, 2014
Tumor-infiltrating lymphocytes from a patient with metastatic cholangiocarcinoma contained CD4+ T helper 1 cells that recognized a mutation in ERBB2IP, and transferring these cells produced tumor regression. Whole-exome sequencing found 26 nonsynonymous mutations, which were tested with tandem minigene RNA in autologous antigen-presenting cells. The first infusion of 42.4 billion TIL, about 25% of them mutation-reactive, was followed by a maximum 30% reduction in target lesions and roughly 13 months of stable disease. At progression, a second product of 126 billion cells, over 95% mutation-reactive, was infused. Tumor regression was seen at one month and continued through the 6-month foll…
Publications
NK Cells
Publication Date: May 9, 2014
Human NK cell products prepared in different ways expanded and homed differently in irradiated immunodeficient mice, and the cytokine given after infusion strongly shaped persistence. Two cGMP products were compared: fresh activated NK cells (FA-NK) made by CD3/CD19 depletion and overnight IL-2, and ex vivo expanded NK cells (Ex-NK) grown with K562 feeders expressing membrane-bound IL-15 and 41BB-L. IL-15 was more potent than IL-2: only IL-15 gave a significant rise in blood NK cells between days 7 and 14 for both products. Cryopreserved cells thawed and infused immediately were recovered in much smaller numbers than fresh cells. Ex-NK cells given IL-15 reached higher numbers in marrow th…
Publications
VST Cells
Publication Date: March 20, 2014
Fusing the IL4 receptor exodomain to the IL7 receptor endodomain converts tumor-derived IL4 from an inhibitory into a growth-promoting signal for tumor-directed T cells. In Epstein-Barr virus–specific T cells, transduction efficiency ranged from 30.4 to 56%. With IL4 at 1,000 U/ml, chimeric receptor T cells expanded to 18.5 × 10^6 cells by day 21, versus 0.47 × 10^6 for unmodified cells, and the modified fraction rose from a mean of 39% to 75% in one week. Growth stayed dependent on both antigen and IL4. In SCID mice bearing IL4-producing tumors, 9 of 28 animals (32%) treated with modified cells were long-term survivors without exogenous cytokine. Untreated mice were all euthanized by day…
Publications
Treg Cells
G-Rex®10
Publication Date: March 4, 2014
Central-memory regulatory T cells (TregCM) are the dominant and most potent Treg subset, supporting expansion of total Treg for adoptive therapy. In 60 healthy donors, TregCM made up 67% of Treg on average, and the naive-to-memory shift with age levelled off after 40 years. Freshly isolated TregCM suppressed early activation of CD4 T cells more strongly than naive Treg, and only TregCM induced apoptosis in responder PBMC. After three weeks of expansion with rapamycin, naive Treg converted mainly to a CM phenotype, whereas effector-memory Treg proliferated poorly. Expansion in a G-Rex®10 device reached at least 50-fold, versus about 20-fold in plates. TCRβ sequencing of ten donors indicate…
Publications
DC Cells
G-Rex®10
Publication Date: March 1, 2014
Umbilical cord blood CD34+ cells cultured in G-Rex®10 bioreactors expanded into myeloid dendritic cells by more than 10^4-fold, far above conventional culture plates. CD34+ cells from five cord blood units, enriched to over 90% purity, were grown with SCF and GM-CSF, followed by IL-4 plus GM-CSF for one additional week. The best bioreactor condition, a five-week culture, gave a median of 1.5 × 10^9 myeloid DCs, whereas conventional plates did not exceed a median of 10 × 10^6 cells. AB serum outperformed autologous cord blood serum, with 1.5 × 10^9 versus 0.011 × 10^9 DCs (p<0.05). After stimulation with Toll-like receptor ligands, the cells produced IL-12p70, TNF-α and IL-6 with low IL…
No manuscripts match your filters.